Reperfusion-induced ventricular fibrillation has been demonstrated in animal models of myocardial ischaemia, but no evidence exists for this in humans. The European Myocardial Infarction Project compared the efficacy and safety of pre-hospital thrombolytic therapy with that of hospital therapy. The objective of this study was to investigate the occurrence of reperfusion-induced ventricular fibrillation in acute myocardial infarction patients following thrombolytic therapy.
Introduction
In animal models of myocardial infarction, reperfusion is followed by arrhythmias, including ventricular fibrillation, which can lead to death if untreated' 11 . It is thought that these arrhythmias result from the oxygen burst associated with reperfusion that is due to enhanced production or decreased scavenging of free radicals, or both'
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Correspondence: Jean-Pierre Boissel, MD, Service de Pharmacologie Clinique, BP 3041, 69394 Lyon, Cedex 03, France. following reperfusion has been reported in randomized trials comparing active treatment against placebo despite the large numbers of patients involved. Whether reperfusion-induced ventricular fibrillation does not exist in human myocardial infarction, or has simply not been observed in clinical trials because of an observational bias, or the time scale was inappropriate, is a matter for conjecture. It is conceivable that the time scale is a critical point since in animal experiments reperfusion arrhythmias occur a few minutes after the restoration of blood flow 1 ' 1 . In clinical trials of thrombolytic agents, the maximum interval for recording ventricular fibrillation events was much longer than this, e.g. 3 h in one trial, ISAM' 4 '. A dilution effect due to ventricular fibrillation unrelated to reperfusion may have reduced the power of previous studies to detect a difference between the incidence in patients who had received a thrombolytic and those who had received placebo.
In the European Myocardial Infarction Project (EMIP) where pre-hospital thrombolysis was compared with in-hospital thrombolysis, emphasis was placed on collecting data concerning the occurrence of early adverse events, including ventricular fibrillation, in order to assess the safety of pre-hospital thrombolysis 151 . Hence, despite the trial being a field trial, and as such, simple in terms of data collection, the EMIP experience has given us a unique opportunity to investigate this problem, although this was not an initial trial aim.
Methods
The EMIP study protocol has been published elsewhere 151 . In brief, from October 1988 to January 1992, 5469 patients were enrolled in the EMIP study by 198 mobile emergency units (MEU) in 15 European countries and Canada. The patients were randomized to receive either 30 units of anistreplase, administered at home, followed by placebo after hospital admission (A/P group), or placebo at home followed by 30 units of anistreplase after hospital admission (P/A group). The study was, thus, double-blind, since each patient received two injections, the first administered by the MEU staff and the second by the hospital staff. Other treatments, both in the ambulance and in hospital, were allowed at the discretion of the investigator.
Study setting
All the participating units had a physician in attendance and all were required to have an ECG recorder and resuscitation facilities (e.g. defibrillator). Before checking eligibility, patients were put on continuous ECG monitoring. All consenting, eligible patients received the first injection (either anistreplase or placebo) and were then taken to hospital by the MEU staff, where they received the second injection (either placebo or anistreplase) and were followed-up until discharge by the coronary care unit staff and/or the cardiology ward staff.
Patients
Patients presenting with pain characteristic of myocardial infarction lasting for at least 30 min, or for less than 30 min but still present and not responding to nitrates and within 6 h of symptom onset were eligible. Excluded were patients who: were receiving oral anticoagulant treatment (aspirin, dipyridamole or any antiplatelet drug were allowed); were known to have haemorrhagic diathesis or a recently active peptic ulcer; had had a stroke, surgery or major trauma in the previous 6 months; had had external cardiac massage for the present symptoms; had systolic blood pressure higher than 200 mmHg or diastolic blood pressure higher than 120 mmHg; were known to be, or suspected to be, pregnant; had had a percutaneous transluminal coronary angioplasty in the previous 2 weeks; refused to give their consent to participate; or were judged to be ineligible for any other reason at the discretion of the attending physician.
Outcome measurements
Ventricular fibrillation was recorded when arrhythmia was observed on the ECG trace and required cardioversion. Ventricular fibrillation complicating acute myocardial infarction was classified as 'primary' and 'secondary'. Primary ventricular fibrillation was defined as an acute electrical event independent of the severity of underlying myocardial damage 161 . In our study, secondary ventricular fibrillation was defined as ventricular fibrillation associated with heart failure or shock. Since the exact times of ventricular fibrillation events were not recorded, we could not compare the occurrences on an exact time scale. However, data on cardiac events were recorded in terms of specific time intervals, such as: prior to randomization; between first injection and hospital admission; between hospital admission and secondary injection, etc.
For all patients, the length of each interval was recorded. For the present analysis of ventricular fibrillation events, five time intervals were considered: (1) between onset of symptoms to randomization; (2) after the first injection up to admission to hospital; (3) after admission up to the second injection; (4) after the first injection up to the second injection; (5) after the second injection up to hospital discharge. The second interval is the most appropriate for the investigation of reperfusion-induced ventricular fibrillation in humans since it is the shortest time interval after the injection of the thrombolytic agent, and both the treated-and placebo-patient groups are comparable due to the randomization and double-blind design of the study. During the fifth interval, following the second injection, all patients would have received treatment, and any reperfusion-induced ventricular fibrillation could have been hidden by other types of ventricular fibrillation. For each of these time intervals, three types of count were performed: (1) the number of patients experiencing ventricular fibrillation in the interval, irrespective of the occurrence of an episode during another interval (total incidence); (2) the number of patients experiencing their first episode of ventricular fibrillation during the interval, i.e. patients who experienced ventricular fibrillation during the interval but not in a previous interval (first ventricular fibrillation); (3) the number of patients presenting their first episode of ventricular fibrillation in the interval and who had not received an antiarrhythmic drug in a previous interval (first ventricular fibrillation without prior antiarrhythmic drug).
All-cause mortality was recorded over 30 days. Mortality due to cardiac causes (arrhythmic and nonarrhythmic), ischaemic or haemorrhagic stroke, other bleeding complications, other vascular causes, or other causes was recorded only during the pre-hospital and hospital intervals. The incidence of non-fatal prehospital and hospital complications was also recorded.
Heart failure was denned in this case as acute pulmonary oedema. Also, the incidence of symptomatic hypotension and symptomatic bradycardia were recorded.
Statistical analysis
For a given time interval the risk ratios (RR) for ventricular fibrillation were calculated by dividing the incidence in the group of patients who had received active treatment by the incidence in the group of patients who had received placebo during the last administration prior to, or at the beginning of, the time interval considered, except where indicated otherwise. The numerators for the risks were the total number of patients at risk at the beginning of the particular time interval. To investigate if a correlation existed between the risk of presenting ventricular fibrillation after administration of a thrombolytic treatment and the delay to treatment, i.e. between onset of symptoms to injection, the data from the two groups were pooled. The number of patients with ventricular fibrillation after the first injection when this was anistreplase was added to the number of patients with ventricular fibrillation after the second injection when this was anistreplase. The same calculation was done for the placebo injection. P values of less than 0-05 were taken to be significant, except in the search for interactions. In this latter case because of the large number of statistical tests performed, we decided to use the more conservative threshold P value of 001, and thus values of less than 001 were taken to be significant. The z-test was used to obtain the P value for the comparison of rates. Since this analysis was not planned in the trial protocol, there was no prior hypothesis of an excess of ventricular fibrillation, and therefore the 'significant' P values should be interpreted with caution.
Results
A total of 5469 patients were recruited, of whom 2750 were allocated to the A/P group and received the thrombolytic agent at the time of randomization, and the remaining 2719 were allocated to the P/A group and received the thrombolytic agent after arrival in hospital. Prior to randomization, 78 randomized patients (1-4%) experienced at least one episode of ventricular fibrillation and 362 (6-6%; 171 in the A/P group and 191 in the P/A group) had at least one episode after randomization; 30 (8-3%) of these latter patients had had one or more episode before randomization. The median duration between onset of symptoms to first injection was 130min (mean =148 min; standard deviation = 82 min). The median, (mean, and standard deviation) of the duration for the four time intervals after randomization were: (1) 35 min (39 min, 20 min) from the first injection up to admission to the hospital; (2) 15 min (20 min, 18 min) from admission up to the second injection; (3) 55 min (60 min, 27 min) from the first injection up to the second injection; (4) 13 days (16 days, 12 days) from the second injection up to hospital discharge. The length of these intervals were the same in both groups.
Although the incidence of ventricular fibrillation was similar in the two groups prior to randomization (A/P group -1-5% and P/A group -1 -3%), ventricular fibrillation occurred significantly more frequently in the A/P group than in the P/A group in the time interval from the first injection up to admission to hospital (Table 1) : relative risk (RR)=l-55 (z=2-32; 7>=0021). No difference was observed between the groups in the time interval from admission to hospital up to the second injection, although there was a trend toward a higher incidence of ventricular fibrillation in the P/A group: 1-6% vs 1-2% (RR = 0-78, P=Q-219) ( Table 1) .
The situation was reversed after the second injection with fewer patients experiencing at least one episode of ventricular fibrillation in the A/P group (who had been given the placebo) than in the P/A group (who had been given the thrombolytic therapy): 3-6% vs 5-3%, RR = 0-68 (z=-3-03; F=0002). The relative risk of ventricular fibrillation for patients who had received a thrombolytic agent compared with those who had received a placebo was similar to the corresponding relative risk observed during the first interval (1-47 vs 1-55).
The overall picture was essentially the same when only the first ventricular fibrillation episode was considered and when the first episode of ventricular fibrillation without prior antiarrhythmic drug was considered (Table 1) . In both instances, there were more patients with episodes of ventricular fibrillation after administration of the thrombolytic agent than after placebo in the intervals following injection, with the relative risks ranging from 1 -77 (first ventricular fibrillation, time interval after the first injection up to the admission to the hospital) to 1-46 (first ventricular fibrillation, time interval from the second injection to hospital discharge).
Sub-group analysis was performed to investigate the existence of any interactions between the occurrence of ventricular fibrillation after administration of the thrombolytic agent and the patients' variables at baseline or after randomization (Table 2 ). Although 15 of the 51 comparisons gave P values of less than 005, only one was significant: an excess of ventricular fibrillation after the second injection in the P/A group related to the site of the infarct (P=0-002). Thus our data do not suggest an interaction with the occurrence of bradycardia, symptomatic hypotension, shock or heart failure. This was true for all three counts of ventricular fibrillation: total incidence, first ventricular fibrillation and first ventricular fibrillation without prior antiarrhythmic drug.
After randomization, 149 patients experienced secondary ventricular fibrillation (21-4% of all patients with either heart failure or shock) and 206 experienced primary ventricular fibrillation (43% of all patients who did not have heart failure or shock). The primary or secondary status could not be determined for seven (2) (3) (4) (5) (6) (7) (8) (9) 62 (2-3) 34 (13) 28 (10) [2] [3] [4] [5] 55 (2 0 
Table 2 Interaction between the excess risk of ventricular fibrillation (all events) after administration of the thrombolytic agent and the patients' variables
Interval (relative risk*; P value) *The relative risk was calculated using the incidence in the group of patients that last received thrombolytic over that in the group that last received placebo. VF = ventricular fibrillation.
patients who experienced at least one episode of ventricular fibrillation. The excess of ventricular fibrillation after administration of the thrombolytic agent was the same for primary and secondary ventricular fibrillation ( Table 2) . The all-cause 30-day mortality in patients with ventricular fibrillation at any time was four times higher than in patients with no ventricular fibrillation (34-4% against 8-5%; z= 12-31; P<0-001). The relative risk of death for patients with primary ventricular fibrillation and those with secondary ventricular fibrillation was 1-39 (z = 2-49; P=0013) and 4-26 (z = 3-28; />=0-001), respectively. No apparent relationship between the incidence of ventricular fibrillation and the difference in the incidence of 30-day mortality between the two treatment groups was observed, as seen from the relative risks for 30-day mortality for each time interval, by treatment group and for patients who did not experience vascular fibrillation and those who did (Table 3) . No relationship between the increased incidence of ventricular fibrillation and the time between onset of symptoms to the administration of the thrombolytic agent was observed (Fig. 1) .
Discussion
In this trial, the risk of ventricular fibrillation was increased by about 50% after the administration of anistreplase, at the time of the first injection, i.e. an average of 130 min after the onset of symptoms. Because of the randomized and double-blind design of this study and the expected recanalization rate with this thrombolytic agent 171 , this increase is likely to be caused by reperfusion of the ischaemic myocardium. The reasons for attributing the excess of ventricular fibrillation to reperfusion are: (1) (8-2) 3-2 0-002 discharge 227/2700 39/100 (390) 188/2600 (7-2) 5-4 <10" Interval between onset of systems and 1st injection Figure 1 Relative risk of a first episode of ventricular fibrillation after administration of the first injection compared with no first episode of ventricular fibrillation after this injection. The number of patients for each hour is indicated between brackets. Each patient is counted twice.
administration of placebo and after administration of anistreplase; (2) the relatively short time frame; and (3) the absence of evidence for any arrhythmogenic action by anistreplase. It would seem that the direct effect of the thrombolytic agent on normal or ischaemic myocardial cells is unlikely since this has never been reported in animal experiments either with anistreplase or with the parent drug streptokinase. However, a direct mechanism cannot be ruled out definitively since the fibrin(ogen) degradation products produced by plasmin-induced lysis of a thrombus can induce transient accumulation of cyclic adenosine monophosphate which, in turn, may play a central role in ventricular fibrillation 181 . However, since this mechanism has only been reported once, we think that the results of our investigation suggest that reperfusion-induced ventricular fibrillation can occur in humans with acute myocardial infarction.
To date, reperfusion-induced ventricular fibrillation has been observed in animal models of coronary ligation and in in vivo models of anoxic-reperfused or ischaemic-reperfused hearts 121 . Evidence for reperfusioninduced arrhythmias in patients can be obtained through two different approaches: either by observing a strict and reproducible correlation between the time of occurrence of the arrhythmia and the time of the reperfusion, or by comparing the incidence of arrhythmias in patients submitted to chemical or mechanical recanalization with that in control patients. The former approach presents practical and ethical difficulties, while the latter is more feasible. However, since ischaemia causes arrhythmias, reperfused hearts may also experience fewer episodes of ventricular fibrillation than control hearts if the duration of follow-up is long enough; this would lead to the concealment of any excess ventricular fibrillation due to reperfusion. This may also explain why no difference in the overall incidence of ventricular fibrillation was observed between the groups if no division into time intervals is used. In randomized controlled clinical trials comparing thrombolysis with placebo or no thrombolysis, a decrease in the incidence of ventricular fibrillation has consistently been found' 4 ' 9 -101 . However, in the ISAM study there were more ventricular ectopic beats, ventricular couplets, ventricular salvos and slow (<, 120 beats . min~') ventricular tachycardia within the first 3 h after the start of the infusion of the study drug reported in the streptokinase group than in the placebo group, but the incidence of ventricular fibrillation was the same in both groups' 4 '. In a trial comparing anistreplase and heparin in patients with acute myocardial infarction, a higher incidence of arrhythmias was found in the anistreplase group within 6h after randomization 1 "'. The authors of a recently published meta-analysis on the rate of ventricular arrhythmias in trials assessing thrombolytic therapy in acute myocardial infarction concluded that the likelihood of developing ventricular fibrillation in the hours immediately following active treatment is similar to that for those who receive placebo, and that thrombolysis does not increase the risk of life threatening arrhythmias' 121 . However, these conclusions are not fully justified since the time delay chosen for pooling the original risk in this meta-analysis was the first day in hospital, which is much too long for the detection of reperfusion arrhythmias.
Although the excess risk after the second injection appears to be of the same order of magnitude as that after the first injection, this cannot be entirely explained by the reperfusion of ischaemic tissue. The early recovery of oxygen supply to the ischaemic tissue in the patients in the A/P group may reduce their risk for ventricular fibrillation unrelated to reperfusion. This could explain why, despite a much longer time interval after the second injection, the dilution effect did not mask the excess of ventricular fibrillation. A dilution effect could explain the absence of an excess of ventricular fibrillation when the data for the interval between the first injection and hospital admission are combined with those for the interval from hospital admission to the second injection, or this may be due to chance alone.
In the EMIP study, the exact time of the ventricular fibrillation events was not recorded, and the lengths of the three time intervals considered are different. Nonetheless, the differences observed between the first two intervals suggests that ventricular fibrillation after coronary recanalization occurs within the first 30 min or so. In animal models, reperfusion-induced ventricular fibrillation is observed very soon after recanalization and occurs abruptly. In patients, full thrombolysis or recovery to at least TIMI grade II in a significant proportion of patients requires between 15 and 60 min, and the thrombolytic agents currently used may induce thrombolysis at different speeds'
131
. In isolated rat hearts, the rate of reflow and reperfusion has no effect on the incidence of reperfusion-induced ventricular fibrillation' 141 ; thus, except if the thrombolytic agent has a direct effect on the myocardium, it is probable that all interventions with a recanalization effect can induce reperfusion-induced ventricular fibrillation.
The plot of the relationship between the susceptibility of isolated rat heart to reperfusion-induced ventricular fibrillation and the duration of ischaemia gives an asymmetric bell-shaped curve, with a high incidence of ventricular fibrillation after 5-10 min of ischaemia and a lower incidence with a longer duration of ischaemia' 1 ' 151 . We did not find this type of relationship between the increased incidence of ventricular fibrillation and the time between onset of symptoms to the administration of the thrombolytic agent (Fig. 1) . However, our approach has two limitations. First, there is a bias for the estimates of the relative risks at each time point because some patients were counted twice, and therefore, no valid statistical test can be performed. Second, the length of the interval of assessment for ventricular fibrillation was different after the two injections. Thus the numbers of cases at each time point in Fig. 1 do not represent exactly the same phenomenon.
The apparently lower all-cause 30-day mortality rate associated with ventricular fibrillation occurring before randomization only, compared with that for patients who experienced ventricular fibrillation at any time, might be explained by a selection bias: patients presenting with a severe condition before entry, including those with secondary ventricular fibrillation, might have been excluded more often. In addition, the allcause 30-day mortality rates for patients who experienced ventricular fibrillation before randomization and Eur Heart J, Vol. 17, February 1996 not later was not significantly different from the allcause 30-day mortality rate for patients who did not experience ventricular fibrillation at any time. This is probably because of the small number of the former patients, and therefore, a lack of statistical power.
In our study, the all-cause 30-day mortality risk was higher in patients who suffered secondary ventricular fibrillation compared with those having suffered primary ventricular fibrillation. This has been observed in other studies' 16 " 191 . The absence of interaction between heart failure or other cardiac complications and the excess of ventricular fibrillation after administration of the thrombolytic agent suggests that the facilitation effect of reperfusion on ventricular fibrillation does not depend on the patient's condition. Since the excess risk of reperfusion-induced ventricular fibrillation was the same for primary and secondary ventricular fibrillation, our data suggest that the facilitating mechanism is independent of the patient's condition and the size of the infarct.
A meta-analysis [20] has shown there was an excess of mortality on the first day following administration of a thrombolytic agent compared with after administration of placebo. Although it is tempting to relate this to our observations, there is no evidence that this excess in mortality is due to an excess of unmanageable ventricular fibrillation. We can, however, postulate a common mechanism, i.e. the phenomenon of reperfusion, although this needs to be confirmed.
The two main limitations of this study are the lack of data concerning the exact time of the ventricular fibrillation episodes, and the mixed population of patients with and without reopened arteries. This latter limitation is explained by the fact that there were a large number of patients and the accepted assumption that more patients who have received thrombolytic treatment will have reopened coronary arteries than patients who have received placebo. The former limitation is inherent in the trial design; however, the shortest time interval (35 min) is much shorter than the corresponding shortest median interval (3 h) 
Conclusion
These data suggest that reperfusion-induced ventricular fibrillation exists in patients developing myocardial infarction who receive thrombolytic therapy. The risk of ventricular fibrillation due to the reopening of the occluded coronary arteries is independent of the complications of the myocardial infarction, i.e. the extension of myocardial damage. However, the increase in the risk of ventricular fibrillation soon after administration of a thrombolytic agent is offset by the benefit of reducing the duration of ischaemia, and the overall incidence of ventricular fibrillation is not increased by the treatment.
